| Title |
Lidocaine Patch (5%) is No More Potent than Placebo in Treating Chronic Back Pain When Tested in a Randomised Double Blind Placebo Controlled Brain Imaging Study
|
|---|---|
| Published in |
Molecular Pain, January 2012
|
| DOI | 10.1186/1744-8069-8-29 |
| Pubmed ID | |
| Authors |
Javeria A Hashmi, Marwan N Baliki, Lejian Huang, Elle L Parks, Mona L Chanda, Thomas Schnitzer, A Vania Apkarian |
| Abstract |
The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when tested in an open labelled preliminary study. Notably, effectiveness of the 5% Lidocaine patch has not been tested against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of spontaneous pain, at baseline and at two time points after start of treatment (6 hours and 2 weeks). |
X Demographics
The data shown below were collected from the profiles of 48 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 14 | 29% |
| Canada | 4 | 8% |
| United States | 3 | 6% |
| Netherlands | 2 | 4% |
| Mexico | 1 | 2% |
| Germany | 1 | 2% |
| United Kingdom | 1 | 2% |
| Comoros | 1 | 2% |
| Unknown | 21 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 41 | 85% |
| Practitioners (doctors, other healthcare professionals) | 5 | 10% |
| Scientists | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Switzerland | 1 | <1% |
| Italy | 1 | <1% |
| Brazil | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 121 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 16% |
| Student > Ph. D. Student | 17 | 13% |
| Other | 11 | 9% |
| Student > Bachelor | 10 | 8% |
| Student > Master | 9 | 7% |
| Other | 33 | 26% |
| Unknown | 26 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 37% |
| Psychology | 14 | 11% |
| Neuroscience | 10 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Nursing and Health Professions | 5 | 4% |
| Other | 12 | 10% |
| Unknown | 32 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2020.
All research outputs
#1,229,065
of 25,371,288 outputs
Outputs from Molecular Pain
#13
of 669 outputs
Outputs of similar age
#7,627
of 250,087 outputs
Outputs of similar age from Molecular Pain
#1
of 47 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 669 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,087 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.